Catalyst Event

Moderna Inc (MRNA) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/1/2026, 12:00:00 AM

OtherSentiment: Positive

Moderna and Merck presented positive 5-year follow-up data for their personalized cancer vaccine (intismeran autogene/mRNA-4157) in combination with Keytruda for high-risk melanoma at the 2026 ASCO Annual Meeting on 2026-06-01. The 49% reduction in recurrence risk is estimated to cause a ≥10% price impact scheduled.

Korean Translation

2026년 6월 1일 ASCO 연례회의에서 암 백신(mRNA-4157)의 긍정적인 5년 추적 데이터를 발표함. 재발 위험 49% 감소라는 획기적 임상 결과로 인해 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline